Top

11-07-2018 | Pediatric | Review | Article

Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

Journal: Pediatric Rheumatology

Authors: Hermine I. Brunner, Lisa G. Rider, Daniel J. Kingsbury, Dominic Co, Rayfel Schneider, Ellen Goldmuntz, Karen B. Onel, Edward H. Giannini, Daniel J. Lovell, for the PRCSG Advisory Council

Publisher: BioMed Central

Abstract

Importance

Specialized research networks are essential to achieve drug approvals for rare pediatric diseases. Such networks help realize the potential of global legislation enacted upon the recognition that most children are treated with drugs whose most beneficial dose and regimen have not been established in pediatric patients. The Pediatric Rheumatology Collaborative Study Group (PRCSG) is a North American clinical trials network that is specialized in the performance of clinical trials of new therapies for pediatric populations with rheumatic diseases. This review provides an overview of the strategies employed by this research network to achieve drug and biologic approvals for children with pediatric rheumatic diseases, particularly juvenile idiopathic arthritis.

Observations

Clinical trial conduct in rare pediatric diseases has required global recruitment. Supported or led by the PRCSG, highly responsive, validated, composite measures have been established to assess drug efficacy. For pediatric orphan diseases with high disease burdens, specialized investigative sites and study designs are needed to complete adequately powered trials at the high standard necessary to enable drug labeling by regulatory agencies. Novel trial designs have been utilized for more efficient testing of innovative drug candidates. All these have been developed or co-developed by the PRCSG research network.

Conclusions and relevance

Specialized research networks in pediatric rheumatology, such as the PRCSG, have changed the landscape of available therapies and improved overall disease outcomes for children with pediatric rheumatic diseases.

Neville KA, Frattarelli DA, Galinkin JL, et al. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.CrossRefPubMed

Rose AC, van’t Hoff W, Beresford MW, Tansey SP. NIHR medicines for children research network: improving children’s health through clinical research. Expert Rev Clin Pharmacol. 2013;6(5):581–7.CrossRefPubMed

Best pharmaceuticals for children act of 2007. Food and Drug Administration Amendments Act (FDAAA), Title V Vol Public Law No. 110-85.

Pediatric Research Equity Act. Pub L; 2003. p. No. 108–55.

Field MJ, Boat TF, Institute of Medicine (U.S.), National Research Council (U.S.). Safe and effective medicines for children : pediatric studies conducted under the best Pharmaceuticals for Children act and the pediatric research equity act. Washington, D.C.: The National Academies Press; 2012.

U.S. Food and Drug Administration. Guidance for Industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). 1999. https://www.fda.gov/downloads/Drugs/Guidances/ucm071579.pdf.

Califf R. Best Pharmaceuticals for Children act and Pediatric Research Equity act - July 2016 report to congress. 2016. https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM509815.pdf.

Turner MA, Attar S, de Wildt SN, Vassal G, Mangiarini L, Giaquinto C. Roles of clinical research networks in pediatric drug development. Clin Ther. 2017;39(10):1939–48.CrossRefPubMed

U.S. Food and Drug Administration. Guidance for industry: pediatric study plans - content of and process for submitting initial pediatric study plans and amended initial pediatric study plans 2016. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm360507.pdf.

10.

Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol. 2004;16(5):566–70.CrossRefPubMed

11.

Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–21.CrossRefPubMed

12.

Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533–41.CrossRefPubMed

13.

Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med. 1986;314(20):1269–76.CrossRefPubMed

14.

Brewer EJ Jr, Giannini EH, Barkley E. Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum. 1980;23(4):404–11.CrossRefPubMed

15.

Giannini E, Brewer E, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebocontrolled trial. N Engl J Med. 1992;326(16):1043–9.CrossRefPubMed

16.

Bass J, Giannini E, Brewer E, et al. Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1982;9(1):140–3.PubMed

17.

Brewer E, Giannini E, Baum J, et al. Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study. J Rheumatol. 1982;9(1):123–8.PubMed

18.

Brewer E, Giannini E, Baum J, et al. Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1981;9(1):129–34.

19.

Brewer E, Giannini E, Baum J, et al. Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1982;9(1):135–9.PubMed

20.

Foeldvari I, Szer IS, Zemel LS, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009;36(1):174–82.PubMed

21.

Levinson JE, Baum J, Brewer E, et al. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1977;91(5):799–804.CrossRefPubMed

22.

Reiff A, Lovell DJ, Van Adelsberg J, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33(5):985–95.PubMed

23.

Sobel RE, Lovell DJ, Brunner HI, et al. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. Pediatr Rheumatol. 2014;12(1):29.CrossRef

24.

Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342(11):763–9.CrossRefPubMed

25.

Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804.CrossRefPubMed

26.

Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106.CrossRefPubMed

27.

Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20.CrossRefPubMed

28.

Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.CrossRefPubMed

29.

Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–7.CrossRefPubMed

30.

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017:annrheumdis-2016.

31.

Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486–96.CrossRefPubMed

32.

De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–95.CrossRefPubMed

33.

Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406.CrossRefPubMed

34.

Giannini EH, Brewer EJ Jr. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. II. Analysis and presentation of data. J Rheumatol. 1982;9(1):114–22.PubMed

35.

Brewer EJ Jr, Giannini EH. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. I. Design. J Rheumatol. 1982;9(1):109–13.PubMed

36.

Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348–52.CrossRefPubMed

37.

Ruperto N, Giannini EH. Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis. 1996;55(1):73–5.CrossRefPubMedPubMedCentral

38.

Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–9.CrossRefPubMed

39.

Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002;29(5):1058–64.PubMed

40.

Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163–70.CrossRefPubMed

41.

Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68(3):566–76.CrossRefPubMed

42.

Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42(7):1354–60.CrossRefPubMed

43.

Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002;46(2):436–44.CrossRefPubMed

44.

Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42(12):1452–9.CrossRef

45.

Ruperto N, Ravelli A, Cuttica R, et al. The pediatric rheumatology international trials organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum. 2005;52(9):2854–64.CrossRefPubMed

46.

Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(9):1213–23.CrossRefPubMedPubMedCentral

47.

Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(5):683–93.CrossRefPubMedPubMedCentral

48.

Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. The juvenile dermatomyositis disease activity collaborative study group. Arthritis Rheum. 1999;42(10):2213–9.CrossRefPubMed

49.

Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric rheumatology international trials organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(11):1533–41.CrossRef

50.

Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheumatol. 2008;58(1):15–25.CrossRef

51.

Boat TF, Field MJ. Rare diseases and orphan products: accelerating research and development. Washington, DC: National Academies Press; 2011.

52.

Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996–2009. J Rheumatol. 2013;40(7):1218–25.CrossRefPubMedPubMedCentral

53.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2014:HYPERTENSIONAHA. 114.04035.

54.

Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol. 2017;52(10):1101–11.

55.

Ruperto N, Brunner HI, Lovell DJ, Martini A. Extrapolation or controlled trials in paediatrics: the current dilemma. Archives of disease in childhood. 2017:archdischild-2017.

56.

Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557–67.CrossRefPubMed

57.

Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti–interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol. 2005;52(3):818–25.CrossRef

58.

PRCSG / PRINTO. Joint Assessor certification. https://prcsg.org/index.php/prcsg-printo-joint-assessor-certification. Accessed 2 Jan 2018.

59.

Yeung RS, Albani S, Feldman BM, Mellins E, Prakken B, Wedderburn LR. Enhancing translational research in paediatric rheumatology through standardization. Nat Rev Rheumatol. 2016;12(11):684–90.CrossRefPubMed

60.

Brachat AH, Grom AA, Wulffraat N, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19(1):13.CrossRefPubMedPubMedCentral

61.

Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(4):688–92.PubMed

62.

Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(6):777–80.CrossRef

63.

Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542–51.CrossRef

64.

Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous Abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759–70.CrossRefPubMedPubMedCentral

65.

De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67(3):840–8.CrossRefPubMed

Medicine Matters Rheumatology

Abstract

Importance

Observations

Conclusions and relevance